Latest / Quantum Potential / Behind the Brain Science of Addiction with Erin Calipari
Transcript
- 0:00The best thing about this job is that, like, I get older, but everyone I work with stays the same age, and, and you get to see how the next generation is changing and how educated they are and how much information they have.
- 0:10I think for them it's, like, yeah, of course you should have both of these things.
- 0:13But what I try to do when I teach classes is explain to them, like, OK, let's say you don't care— this isn't something that like, is you're passionate about.
- 0:20Let's talk about how studying sex differences can actually be used as a mechanism to understand fundamental aspects of biology.
- 0:28My guest today is Erin Calipari.
- 0:30She's currently an associate professor in the Department of Pharmacology at Vanderbilt University.
- 0:36Her work focuses on understanding the neural circuits that govern motivated behaviors, with particular attention to how these circuits are altered in addiction and psychiatric disorders.
- 0:45Dr. Calipari is known for integrating behavioral, molecular and circuit- level data to create comprehensive models of brain function.
- 0:53Over her career, she has published over 95 peer- reviewed research articles and reviews on these topics.
- 1:12Welcome to 'Quantum Potential,' the podcast dedicated to curiosity and discovery.
- 1:17My name is Cybele Raver, and I serve as the provost of Vanderbilt University.
- 1:21As a leader in higher education and as a social scientist, I believe that we can transform higher education for the 21st century.
- 1:28At my core, I am wildly curious about other people's work, whether it's in science, the social sciences, the humanities or the arts.
- 1:36This podcast gives us the opportunity to break open new ideas through discovery and creative expression.
- 1:48So one big piece of news, and I'm so excited, is that Calipari has recently been named as the new director of Vanderbilt's internationally renowned Center for Addiction Research.
- 1:58And through cutting-edge biomedical research at the intersection of systems, neuroscience, drug development, engineering, computer science and more, Vanderbilt's Center for Addiction Research is making a difference in the struggle against drug addiction.
- 2:11In her role as director, Calipari is leading a large group of faculty, students and staff as they work together to understand the brain's responses to novelty and reward and the factors that place some of us at greater risk for addiction.
- 2:24So welcome, Erin.
- 2:25I'm so excited, and thank you so much for all that you do, both in science and in terms of the impact of your work on the wider world.
- 2:33It's really exciting to have you.
- 2:34Yeah, I'm excited to be here.
- 2:36So one of the things that I could talk about...
- 2:38I mean, there are a million things that we could start with, but I would be really great if you could just help us by zooming out a little bit to help us understand—what does learning have to do with drug addiction?
- 2:49This, this is ...
- 2:50You're such an expert in both, right?
- 2:51This is so funny, because I always ask my lab, you know, "Why should someone care?" right?
- 2:55We, we get in the weeds of science, and we're doing these really nuanced experiments.
- 2:59And I always ask them before we write the paper, "Why should someone care?" When people think about addiction, I think the first thing they think about is just the drug itself.
- 3:07But lots of people take drug, and they don't develop a substance use disorder.
- 3:11And so when you start to look at addiction at its core, it's really a dysregulation in how an individual learns.
- 3:18So, you know, when you're thinking about learning, there's, you don't just learn about the drug experience, but you learn about all the things associated with that drug experience.
- 3:25You learn about cues—things like the bar you were in, where you were when you took the drug, who you took the drug with—and all of those things become triggers for relapse.
- 3:35And so then you have that aspect of learning, and then you have this other aspect with, you know, comparing drugs to other stimuli.
- 3:43So when you have substance use disorder, you're taking drug in the face of negative consequences, other alternative rewards, and so it's really this dysregulation of how we make decisions about drugs relative to everything else in our lives.
- 3:58So interesting.
- 3:59I mean, I was just listening to a podcast from a British group called One Year No Beer, and they were talking about how when they go into a bar, when one of the co-founders goes into a bar, he goes in with the intention of not ordering a ... a beer, and he thinks he's gonna order a sparkling water.
- 4:16But the minute he stands up next to the edge of the bar out from his mouth comes, you know, "I'll have a pint." Yeah.
- 4:23Right?
- 4:24So that idea of cues and learning makes such so much sense.
- 4:27And how we make decisions, what you know, I mean, your brain is kind of created to really efficiently do things.
- 4:33So, you know, doing things out of habit actually is really a good way for us to automate things.
- 4:38The problem is when the thing that becomes automated is drug use, now you have an issue with how do we rewire these?
- 4:43How do we learn? What factors are influencing that?
- 4:46And that's really what we study.
- 4:48So interesting.
- 4:48And so that's where you're talking really about habituation.
- 4:52Mm-hmm.
- 4:52And, uh, novelty, right?
- 4:54Yeah.
- 4:54Really cool.
- 4:55So one of the things that I loved about your new paper in 'Nature and Neuroscience' is that you really focus on the role of dopamine signaling in the nucleus accumbens to better understand the neural processes that underlie learning.
- 5:07Yeah.
- 5:08I think because you're going to take us eventually, um, to how that connects to addiction.
- 5:12But first you're really breaking down, um, the process of learning.
- 5:15Yeah.
- 5:15So, just give us a quick primer, two minutes about what do we wanna know about the nucleus accumbens? Yeah. It's a tiny portion of the brain, right?
- 5:22Yeah.
- 5:23So it's, it's my favorite brain region.
- 5:25I always tell my neuroscience students, you have to have a favorite brain region.
- 5:27Mine's the nucleus accumbens.
- 5:29So it's a brain region that's really tied to reward.
- 5:34If something is valuable to you in some ways, it's a region that's very active.
- 5:38It's something involved in kind of linking cues and then outcomes, so you learn that something in your environment means something, and you do something in response to that.
- 5:46It's really at the key. It ...
- 5:48it's really central to that.
- 5:49And it's a brain region that we know is really important for just reinforcement in general— will you do something over and over again.
- 5:58And it's something that's very highly dysregulated in ... in substance use disorder.
- 6:03So it's kind of key to this, kind of, limbic system of "Will you do it?
- 6:07Is it good?
- 6:08Is it bad?
- 6:09Should I do it again?" Cool.
- 6:10So is that the section of the brain that's being recruited by TikTok?
- 6:13Yes, actually, yes.
- 6:14And I actually that, so this is, you know, it's funny you brought this up.
- 6:17So a lot of these social media, all these things are really engaging these same circuits in the brain that respond to things that are good, things that make us do things again.
- 6:26And so you get a lot of activation in these limbic structures just by the... how these social media apps are really engaging you to interact with them.
- 6:35And so this, there's a lot of overlap in the circuits engaged by drugs, food, rewards and social media, which I think is an interesting...
- 6:42Totally cool.
- 6:42...interesting thing.
- 6:43OK, so we'll get there in a minute.
- 6:45Yeah.
- 6:45So, OK.
- 6:46This little part of the brain starts firing away, and, tell me how dopamine plays a key role there.
- 6:52Yeah, so, so one of the, the kind of earliest things about drugs of abuse is people for a long time were kind of like, "What, what is the thing that makes us want to do them over and over again?" And so.
- 7:03Drugs of abuse, all of them— you know, you think of opioids, you think of stimulants, you think of nicotine, alcohol— every one of these drugs increases dopamine in this brain region.
- 7:12And so, you know, in a normal situation, dopamine is increased in your brain, in your brain in this same region in response to things like food, pleasurable experiences— and drugs do this pharmacologically.
- 7:24And so it's really that key site of those initial drug actions that are really important for motivated behaviors.
- 7:32But it's also a key site that really helps us identify if things are important to us or not.
- 7:36And so that's not just relevant to drugs, that's also relevant to any behavior, right?
- 7:40You put your hand on a hot stove, you learn very quickly— do not do that again.
- 7:45That nucleus accumbens is at the center of, kind of, that kind of adaptive learning.
- 7:49"Is it important?
- 7:50Should I do it again?
- 7:51Yes or no?
- 7:52Should I pay attention to it?" Got it.
- 7:54And I really appreciate you inserting the hand on the hot stove.
- 7:58So it could be super pleasurable— I could be out completely vibing on the green plant life when I'm having a run and soaking it all in.
- 8:06Yeah.
- 8:07And that could be really rewarding.
- 8:09Or alternately, I could be facing something scary or painful.
- 8:13Yeah.
- 8:13Yeah.
- 8:14Well, and I think, so I, a lot of the work in my lab when I started here at Vanderbilt was really focused on understanding how dopamine is involved in reward.
- 8:21Because that's really how we think of it— we think of it as this reward molecule.
- 8:24But our really early work started to realize that dopamine is not just increased by rewards.
- 8:29It's also increased by things that are not pleasurable.
- 8:33And so what we were finding is that dopamine goes up anytime something is important and something you should pay attention to.
- 8:40And so that could be good, bad, just something new that you hadn't noticed before.
- 8:46And so it's really there to kind of grab our attention and help us decide—should I do that again?
- 8:50Should I change my behavior?
- 8:52Is everything OK?
- 8:54Totally clear from your papers.
- 8:56And what I love about your papers is that you do that in a really intense, but very elegantly ...
- 9:03You're like, "Oh, nothing to see here.
- 9:05Just, you know, hold my beer and watch this.
- 9:07Or hold my..." You know, just amazing.
- 9:09Yeah.
- 9:09Because you block and tackle each possible other alternative hypothesis.
- 9:14And it sounds like you're going up against a really foundational theory, right?
- 9:19I remember the Rescorla–Wagner model...
- 9:21Yes.
- 9:21...right?
- 9:22Which was really that learning is really based on reward.
- 9:25Yeah.
- 9:25Um, and based on trying to close the gap between, uh, whether I get the reward today or whether I'm gonna get the reward if I learn something more, right?
- 9:34Yes.
- 9:34And you take that on in this like,"Oh, just, just checking," but in fact, I feel like there's this real amazing punch, counter-punch energy to the way in which you really work through every single counter hypothesis.
- 9:49Am I making that up or?
- 9:50No.
- 9:50You're, you're bringing back memories of my, my early years.
- 9:54I think that when I started on the, in the space, that goal wasn't to be like, "Oh, dopamine doesn't do this." It was this ...
- 10:02we had just gotten some new tools, which we can talk about, and I think that that let us look with unprecedented resolution into these, kind of, very fast dopamine signals.
- 10:12And we were just, like,"Let's see what happens." And when we started looking at the data, we were like, "Oh, this looks a little different than what we thought before." And so the problem ... or not the problem, the science is science, the data are the data ...
- 10:24it's when you're going up against a theory that people really like, because it's simple, it explains a lot of things, it's very challenging in a way? But in, in a ... challenging sounds bad.
- 10:37It's, it's exciting. But it means that the burden of proof is basically, again, like, you have to show ...
- 10:44You're the underdog.
- 10:44...every alternative.
- 10:45And honestly, I think on some level, when I was pre-tenure, I think I was, like,"Oh my gosh, am I ever gonna make tenure?" But looking back, it really held my science to a standard that I'm proud of, because it was, it wasn't just like, "Oh, here's a cool observation." It's, "Here's a cool observation, this is what we think and this, this, these are all the possible alternatives." And we did it being open to being wrong.
- 11:07Like, we weren't doing it to prove we were right.
- 11:10We were doing it to really systematically say, "Is it X, or is it Y?" And I think that's the most fun way to do ...
- 11:16I mean, that's the cool thing about academia, is that you're just trying to find out the truth.
- 11:20And that's what I find really exciting.
- 11:23But it is really hard when you have a theory, maybe, revising it.
- 11:26Very, very impressive.
- 11:28I mean, just in terms of really being eloquent about the power of discovery, right?
- 11:33That you're clearly getting evidence that some foundational theory that we've all been taught in our own early days, um, may not actually be fully, you know, as, as truth-based or as evidence-supported...
- 11:48Yeah.
- 11:49...um, as your new evidence is suggesting.
- 11:49How is it to train students in that?
- 11:53Especially when I think, you know, it's not that it has a competitive feel, but it definitely has a, like,"Persist until you've absolutely, you know, gone to the mat." Yeah.
- 12:04It's ... OK, so I think it's ...
- 12:07it is a journey.
- 12:09But I think, you know, one thing that makes Vanderbilt special is that we have students that are just, they have this spirit of kind of, like, a pioneering attitude.
- 12:18They are just excited to, like, do it, right?
- 12:22And they're so amazing and high- achievers that it's, you look at them, and I think—when we started down this path, any of these paths we've been on, because a lot of my work has been, like,"It's not really what you think it is"— we always have a conversation at first where I'm, like,"OK, there's ... there's always a million ways you can go with a project." And it's, like, "Do you wanna go this easy way where it's, it's, like, dopamine is up, let's see how drugs affect that." That's not bad.
- 12:46It's actually really important too.
- 12:47Or, you know, "It looks like we may have this potential to really revise how people think about things.
- 12:52But just so you know, this is going to be a really challenging path.
- 12:56But it'll be very rewarding." And the students here are always, like, "I want that one.
- 12:59I want the hard one that's gonna revise how we think about things." And so it's, it's a really great opportunity for mentorship, too, where you start to explain to them, like, if people are questioning you, that's OK.
- 13:10Ask them what experiments they want to see that would convince them—and then do them.
- 13:31I wanted to talk a little bit about that, um, method that you were starting to...
- 13:35Mm-hmm.
- 13:35...um, discuss—this idea of optogenetics.
- 13:37Yeah.
- 13:38When I read this, I was like, wait, wait, wait.
- 13:40Yeah.
- 13:41So cool.
- 13:41So can you just, um, read from your paper, this is just even on the first page of, um, the 'Nature and Neuroscience' 2022.
- 13:48OK, now we gotta, we gotta hope there aren't typos or mistakes as I'm reading this again for the first time.
- 13:53OK.
- 13:54The development of genetically encoded fluorescent dopamine sensors allows for direct optical assessment of dopamine transients in vivo with high signal-to-noise ratio.
- 14:03OK.
- 14:03Slow.
- 14:04So.
- 14:04Yes.
- 14:05Optical?
- 14:05Yes.
- 14:06OK.
- 14:06So you're...
- 14:07So it's using light.
- 14:08OK.
- 14:08So, so the, the, some of the biggest advances in the systems neuroscience field, probably in the last 10 years, is our discovery of these different kinds of proteins that are sensitive to light.
- 14:21Got it.
- 14:21And so there's, there's a couple kinds.
- 14:23There's, there's some that are sensitive to light in the way that they basically can cause a cell to fire.
- 14:28So the way our brain communicates is cells fire, they transmit information from one neuron to another, and it's how we transmit signals.
- 14:35So we can actually use a laser to turn cells on or off with very high resolution.
- 14:42So I can say in an environment we turn on a light, but I don't want dopamine neurons to turn on then.
- 14:49I am gonna use a laser to turn them off.
- 14:51Or we can say, you know what?
- 14:52I'm gonna do something else.
- 14:54I just wanna turn dopamine neurons on and see what the animal does.
- 14:57So we basically are remote- controlling model organisms.
- 15:01Amazing.
- 15:02The other class that we also use that I think is, is just as exciting, is there are these proteins that fluoresce when a molecule binds to them.
- 15:12So there's, they're for all kinds of things.
- 15:14The ones we use, when dopamine is released in the brain, they bind to this protein and they emit light.
- 15:19So what we're able to do is actually record that light, and they do it really quickly.
- 15:25So now what we can do is we can turn dopamine neurons on and off.
- 15:28And we can use, like, optics to record dopamine release, but with, like, sub-second resolution.
- 15:36So second to second, we can say how much dopamine is in the brain.
- 15:39And we can look and say, "OK, if there is a behavioral task where a cue comes on, you have to push a button and then you get a reward, we can separate out the dopamine responses to each part of that task independently." And so now you have all of this data where you can...
- 15:54So it's real-time?
- 15:55You've basically you're able to It's real time.
- 15:56You're able to...
- 15:57You were...
- 15:57You know...
- 15:58Watching...
- 15:59Wow.
- 15:59You were watching on a computer screen, the dopamine going up and down, while a task is being performed.
- 16:05And then you can go and say, "Well, if this pattern does ... we think it does X," we can turn that off and say, "So then the behavior should, should change in that way." Far out.
- 16:14Yeah.
- 16:14OK.
- 16:15So you use that tool...
- 16:16Yeah.
- 16:16...to then be able to figure out exactly what you were saying, right?
- 16:19Yeah.
- 16:19That it's not necessarily reward...
- 16:21Yes.
- 16:21...that is leading to learning, but it's actually novelty.
- 16:24Exactly.
- 16:24So, so I think, you know, you brought up Rescorla–Wagner and these these different theories, and so one of the kind of ...
- 16:31You know, I'm like, I don't wanna say I'm, I'm a like half psychologist, half systems neuroscientist.
- 16:36The, the learning theory field has made some really cool models.
- 16:39And what these models do is they predict what behaviors should do in different cases.
- 16:43And so what you can do is say, "OK, if dopamine was encoding reward, if we turn on dopamine neurons at this time, then the animal should do this.
- 16:52But if it's encoding novelty, it should do something else." And so we kind of used those previous models and what we thought would ha would happen, and we designed experiments that depending on what we did, the animal would do something different if we were right or they were right.
- 17:06And so what we did is we went through and we said, "OK, let's just record dopamine release to novel stimuli." Novel's just something new, something you've never seen before in the environment.
- 17:15If dopamine is a reward signal, a random light shouldn't really do much to it.
- 17:20But if it's signaling that something new and important is here, regardless of whether it's good, bad or whatever, we should see this dopamine response.
- 17:26And so what we found was that when we gave animals kind of irrelevant information, dopamine would go up.
- 17:32But as they became habituated to it, they experienced it for a long period of time and they learned, "Oh, that's actually not important to me." Dopamine slowly went down.
- 17:40And so what we found was that dopamine was really, like, kind of stamping in these important unexpected events—regardless of whether they were something good, bad ...
- 17:49it was just, "Was this new?
- 17:50Is it different than I expected?
- 17:52Should I do something?" So fascinating.
- 17:54Because, right?
- 17:54I mean, it makes so much sense from the perspective of this massive number of percepts coming into our brains through our visual field, our auditory field all the time.
- 18:02Like, there's just a bajillion things hitting my brain all the time.
- 18:06And how is it that I'm gonna learn that, that, you know, some cue in the world is important for me— either because something really awesome is gonna happen if I go toward it or something not so good.
- 18:16I mean, so tell me a little bit about latent inhibition, right?
- 18:20This idea that we habituate could actually be a challenge in terms of learning, right?
- 18:24Yeah.
- 18:24So, so, OK, so this is such a good ... the, the point you just made is so important.
- 18:28Like there's, OK, you can think of the world, you know, in one way there's unlimited amount of things in your environment, right?
- 18:34You're in a studio, there's a microphone, there's lights.
- 18:37You don't have to learn that this microphone doesn't mean I'll get ice cream.
- 18:41This microphone, you don't have to make an infinite number of relationships between things.
- 18:46What you do is you say,"Is this thing important?
- 18:49Does this predict something that I need to pay attention to?
- 18:51Or does it not?" And if it doesn't, you can ignore it.
- 18:54And so the idea of latent inhibition is when you've experienced something irrelevant to you that you learn to ignore it.
- 19:00And so what happens now, is if you were to need to learn something new about that, it takes a little bit longer because you're not paying attention to it.
- 19:07Yeah.
- 19:07I immediately thought of the temperature gauge light in my parents' VW bug.
- 19:12Because it's broken, and it's always been broken.
- 19:15It's always on.
- 19:16And so of course I totally disregard that little light, right?
- 19:20Yes.
- 19:20But, like, one day I'm gonna be in a car...
- 19:22Yeah, yeah.
- 19:23...and that light's gonna go on, and it's gonna mean, like,"Your car is overheating," but it won't probably register.
- 19:29That, that's such a, it's such a good example though, right?
- 19:31Is that that light normally would mean something, but then you learn over time,"Actually, this doesn't mean what I thought so now I ignore it." And so this is just, it's a fundamental process that we use in an environment to just ignore irrelevant things and efficiently learn.
- 19:43And so it's, the reason that it was so interesting to me is that it's actually one of the violations of those previous learning theory models.
- 19:50And so those models were developed to just make predictions about a cue and an outcome.
- 19:55And one thing they didn't do well is when a cue didn't predict an outcome and you learn to ignore it—which we know happens.
- 20:02And so our kind of idea was, OK, well, if dopamine is encoding these predictive learning algorithms, it should be able to be predicted that what the signal looks like by these models.
- 20:12But if it's actually doing something different, like signaling novelty or important things, it should actually track this behavior in a way that can't be predicted by other models.
- 20:21So we were, I guess, using some really niche, in-the-weeds theories.
- 20:26But then when you take a step back and you say, "Who cares?" My parents aren't academic, so they're always, like, "Who cares?" And it gives me this idea of, like, why should someone care?
- 20:34Well, because how we learn to allocate attention is really important for how we learn.
- 20:37And if there's dysregulation in that, you start to get deficits in behavior, adaptive learning.
- 20:42And you see that with a lot of disorders that are characterized by dopamine dysfunction.
- 20:46Right.
- 20:47You mentioned Parkinson's as an example, right?
- 20:49And does it have anything to do with addiction, or is it really primarily in these psychiatric disorders with, um, dopamine, uh, dependent pathways?
- 20:56Yeah.
- 20:56Yeah.
- 20:56So the reason that I ended up in this space...
- 20:59So my lab is like half learning theory, half really hardcore what is, what are drugs do to your brain?
- 21:05And so some of my early work had really focused on how long-term drug use changes dopamine release in the brain.
- 21:10And it basically showed that across almost all drug classes we tested, that long-term drug use leads to reduced dopamine responses.
- 21:18So you just have less dopamine responses to kind of everything, including the drugs themselves.
- 21:22And my question was always, well,"What does that mean to an individual?" You have less of a dopamine response.
- 21:28What does that mean— not just to the drug, but outside of the drug context?
- 21:32Got it.
- 21:32So the walk in the park is no longer as green.
- 21:34Exactly.
- 21:34And or new, new information to you, it doesn't update your behaviors efficiently.
- 21:39So, why should you care?
- 21:41Well, because let's say you're really bad at updating behavior.
- 21:43That means— drugs, like, you learn that maybe a drug cue... a bar ... doesn't mean you're drinking all the time anymore ...
- 21:50it's gonna take you longer to extinguish that because there's new information, but you're not processing it.
- 21:55It's going to cause you to not evaluate negative consequences of your outcomes because that's new or your behavior, that's new information.
- 22:03So you take drugs, something bad happens.
- 22:05You're not going to respond to that as efficiently, and you're not going to respond to alternatives.
- 22:11So now you have a situation that kind of starts to explain why these dopamine deficits are causing behaviors that aren't just about drugs— they're also about their relation to other stimuli in your environment that are not drugs.
- 22:23So I'm just imagining you're sort of insulated from the importance of new information.
- 22:28Yeah.
- 22:29What, what did you do in the past?
- 22:30And it makes sense, right?
- 22:31That's why people who've used lots of drugs keep doing that.
- 22:34That remains for a very long time.
- 22:36But they, they have a hard time learning new things.
- 22:39And these, these kind of deficits in decision-making are actually very predictive of outcomes with abstinence.
- 22:45So people who have less deficits or fewer deficits outside of the drug context, those people actually have better, better outcomes long term.
- 22:52So interesting.
- 22:52It also makes total sense.
- 22:54It's something like a 12-step program where you repeat the same pieces of information and the same guiding values over and over for years, right?
- 23:02Yeah.
- 23:02I can understand, then, a little bit why that makes sense from that perspective, right, of the difficulty you'd have to update.
- 23:08Right, and you're reflecting, and those, those things are effective.
- 23:10One, because you have community that holds you accountable, but two, because you're reflecting on your actions and outcomes, you're actually intentionally cognitively saying,"I did this.
- 23:20Was that good?
- 23:21Should I What did I learn?" Yeah.
- 23:22"What did I learn?
- 23:23Should I update it?" So in some ways, it's really making you pay attention to something maybe that you wouldn't have otherwise.
- 23:30And so then you start to think about, kind of, what this means, how you start, you know, conceptualizing how you help individuals.
- 23:36And I think that it, it kind of just sheds a new light on kind of why these problems emerge and how you can start to think about addressing them.
- 23:43And is there, in terms of how to address them, do you feel that it directs you towards a, a novel or an innovative approach?
- 23:50So here, here's the thing that's really hard is, like, we do not have a treatment for addiction.
- 23:55We have drugs that help people take less drug or that help with overdose.
- 24:01But there isn't, like, a pill you take that cures addiction.
- 24:04So right now what we rely on is these kind of interventions, 12-step programs, cognitive behavioral therapy.
- 24:10But when you're really thinking about the behavioral aspect of what these deficits mean, I think it really does help you start to one, humanize people and think about addiction as kind of this brain disorder that's changing how we make decisions.
- 24:22But also start to think about how you would start to help people in that space.
- 24:26And so creating a drug that reverses dopamine deficits is really challenging.
- 24:31Because it's just, it's a system you need for everything.
- 24:35You can't just block dopamine and say, you know, "If you block the dopamine system early on, people won't take drug." But they also, they feel terrible.
- 24:43They wouldn't eat.
- 24:44They wouldn't interact with people.
- 24:45Quality of life would be...
- 24:46So you're, you're trying to figure out, like, what systems do we target and how do we do it?
- 24:49And so, you know, I think it does start to get you towards, "Well, how can we fine-tune this system?
- 24:53Are there drugs that maybe would boost it a little bit at key times?" And so.
- 24:57We're early on there, but you know, we have a lot of people here studying that from different angles, so it's really exciting.
- 25:02Yeah, I mean, I love that the social impact of simply de-stigmatizing some of those behaviors and understanding that, um, you know, learning, uh, about the consequences of one's behaviors is harder under those conditions because of, of what's being blunted in terms of dopamine response—is really huge in terms of just opening people's understanding.
- 25:25Well, and I think that's why, you know, things like this podcast where, where you really think about, like, you know, the public, they're smart.
- 25:33They're smart people who want these, this kind of information.
- 25:36And so when you start to think about things critically, but it's, I understand why it's hard, if somebody's in your life and some of their actions have harmed you, to dissociate those things from the science behind it.
- 25:48But I do think the first step is trying to explain to people kind of what this is and, and really understand that from that aspect.
- 25:56Because when you de-stigmatize these disorders, then people can, they can get help, people can, can, you know, you can help your peers and your colleagues and your family, and you can start to think about exactly how to intervene.
- 26:07And it's, I think it's the first, it's a hard first step, because everyone's not always willing to listen.
- 26:11But, like, as a society, I think with the opioid epidemic, we've started to have those hard conversations.
- 26:15And it's been exciting to see the, kind of, public opinion change.
- 26:20Change.
- 26:21Absolutely.
- 26:22So amazing.
- 26:23So let's shift to a different tool that you've used, um, which I just completely, um, was super excited to read.
- 26:31Um, which is your use of economic, um, uh, theory and principles and measurement to look at, um, how much uh, an individual—in this case a rodent—is willing to "pay," quote unquote, like the what, what price are they willing to pay for cocaine?
- 26:48Yeah.
- 26:48Right?
- 26:48So, um, tell us a little bit about this remarkable study that, uh, looks at a bunch of different things, including gender differences or, I guess, sex differences.
- 26:57I guess mice don't have gender, but Yeah.
- 26:59Um, sex differences in, um, rodents.
- 27:02But you are also using this really cool tool to figure out how to estimate how hard we're willing to work.
- 27:09Yeah.
- 27:10Yeah.
- 27:10OK.
- 27:10So I, I, again, like a lot of my stuff is really focuses on, kind of, behavioral, behavioral measures that you can actually start to think about across species ...
- 27:19across species.
- 27:19So, you know, one of the hard things is doing work that's really mechanistic.
- 27:24We talked about optogenetics and optical tools— you can't do those in humans.
- 27:27So how do you start to take the work in that space and actually translate it into humans and primates to really understand, kind of, what things are translatable and what what aren't.
- 27:38And so my background is, um, is drug self-administration.
- 27:42So these, these tasks are actually kind of cool.
- 27:43What you do is you put rodents in boxes, and you let them push buttons.
- 27:47And so the interesting thing is just like humans, they'll take lots of drug. But you can start to make the the task or the game to them harder.
- 27:56You can say, "OK, if we make you press a singular time on this button to get drug, how much will you take? ...
- 28:03If we make it harder for you, how much will you take?" It's kind of like asking a person,"OK, if I gave you a candy bar for 10 cents, would you pay?" You're like, yeah.
- 28:11A dollar?
- 28:12OK. $5.
- 28:13You're like, "Well, it's getting kind of pricey." Then all of a sudden it's like a hundred dollars and you're like, "I don't know." It's that right?
- 28:19You have to drive two counties away...
- 28:20Yeah.
- 28:21What?
- 28:21What?
- 28:21...to get the Snickers bar, you're not gonna get up out of bed and drive those two counties unless you really, really want it.
- 28:27Unless you really want it.
- 28:28And that's really what we're asking is, "How much do you want this?" And so what you're able to do now is essentially look at the price they're willing to pay— we do it in effort, like "How much will you press to get the amount of drug you want?" And you can actually use these, these equations that are—they're economics equations—to say, "What's the maximum you're willing to pay for how much drug you want?" And then you can look at how that differs, not just across sex, species ... but you can, you can start to compare these because you can do similar studies in humans.
- 28:58And so what we can do here is look at sex differences.
- 29:01And so in one of the big parts of my lab is really studying how biological sex and hormones influence how drugs work and how we learn about them.
- 29:11And so in the study, what we were doing was looking at whether hormonal cycles were predictive of how much they're willing to pay, or whether they were influencing how individuals were learning about drugs and outcomes.
- 29:23And so what was kind of cool was that, you know, males and females would, would pay in many cases, the same amount, unless there were drug- associated stimuli present.
- 29:32And so this kind of gets at this far context situation that it can influence how much you consume and how hard you're willing to work.
- 29:40And so we're looking at how hormones influence that.
- 29:42And it's a, I don't know, it's a kind of cool cross-disciplinary series of studies, where you can look at all these things and pull from different fields.
- 29:50Totally.
- 29:51And what I thought was fascinating about your findings was that they were really complex, right?
- 29:58Yeah.
- 29:58So I think, as I recall, there are no sex differences between the male and female rodents when there are no cues.
- 30:06Yeah.
- 30:06When they, when they have access to the drug, but they weren't basically learning about the use of the drug or the cue. But that the cue-specific differences arise when the female rodents are in their estrus cycle.
- 30:20Yeah.
- 30:20So, so when hormone levels are high, which is for, that's, that's estrus.
- 30:23When you have high ovarian hormones, what it's doing is it's influencing— they say it's basically strengthening the relationship between drugs and outcomes.
- 30:30And so essentially those drug cues have a way larger, like, effect on behavior.
- 30:36And so the...
- 30:37the "Why should you care?" So essentially what what it's showing you is that how males and females are interacting with their environment is different.
- 30:45And the female...
- 30:47the female environmental interactions and learning are really highly dependent on ovarian hormones and kind of the when they're high and how they're interacting.
- 30:55And I think in a ... in a normal situation, these kind of hormone effects on motivation and learning are probably really important for survival.
- 31:03They help you learn where food is.
- 31:05They help you learn about safety and really adapt behavior.
- 31:08But then drugs are hijacking these same systems.
- 31:10And so it's kind of acting on a system that's there to keep us safe, and then hijacking that in a way that makes you learn that drugs are more potent drivers of behavior.
- 31:20Amazing.
- 31:21So the question that I then have for you as a scientist.
- 31:24And this is just flashing on my own experience, you know, coming up at various points in various eras, is—can your public, can your audience grasp the complexity?
- 31:36Like do you find that they understand the complexity of what you just said, or do you find that they go straight to, you know, males and females are different when it comes to drugs.
- 31:43And, you know, they cut to a chase that you didn't actually intend?
- 31:48I think it depends.
- 31:50I think the question I get a lot.
- 31:51So some of our earlier work was looking at hormones and how they potentiate drug effects, and they're just basically showing that hormones can influence how much dopamine increases with cocaine.
- 32:01The first thing people ask is oral contraceptives.
- 32:03So if people are taking birth control, does that make them more or less likely to be addicted, right?
- 32:07And when you start to translate...
- 32:09I would not have gone there.
- 32:10It's, it's everybody goes there, but when you start to translate the findings to humans, you have to understand that it's ... there's a complex set of factors.
- 32:18Why does someone take the drug in the first place?
- 32:20Could be wildly different.
- 32:21It could be to avoid stress or depression, or it could just be to, like, be social with friends.
- 32:26Those are fundamentally different, and so we look at these very controlled scenarios and we say, "Oh, well only under these conditions." But in humans there's just, like, an infinite set of scenarios— your social life, your socioeconomic status, your environment—why you're taking drugs. Do you have injuries or, you know, other psychiatric diseases?
- 32:45And so...
- 32:45Or I was even just thinking maybe the somatic experience of having a high hormonal level is, you know, one that a, a, an an organism—whether it's a rodent or a human—wants to blunt.
- 32:55Right.
- 32:56Right.
- 32:56So a female human would be like, Right, I am really cranky and feeling achy and...
- 33:00Yeah, that's actually a really good, I hadn't thought about that.
- 33:03I thought about this, the, the hormonal in the hormonal experience being a cue in and of itself.
- 33:08But like, I think this is the thing is like we get in the weeds and then the question is how do you bring it back out in a way that people understand?
- 33:15And I think these kinds of podcasts and ways where you can really talk about this at a level that's maybe scientific, but also kind of explains the nitty gritty— or just like, I think it's the, the kind of first step to really making an impact.
- 33:28And what is your lab, um, do they just go super into, are they, do they go completely wild for being able to ask those kinds of questions?
- 33:36Or are they like, "Whoa, too complex! Please give me a clear two-by-two that I can test in a semester." I mean, you talked about everybody being super ambitious, Yeah.
- 33:44but I would imagine questions around, um, sex differences might, um, be either really exciting to students...
- 33:51Yeah.
- 33:51...or feel like, "Whoa, this is way more than I wanna take on." I think you get both because it is, it is really hard— How do you take something that's high hormone, low hormone times, male, female?
- 34:02Also different developmental periods, right?
- 34:04Hormones change over the lifespan.
- 34:06And how do you make something that has a testable hypothesis that your statistics can actually pull out a difference.
- 34:13Yeah, and I think that we spent a lot of time in the lab designing studies to answer like one question.
- 34:18Not just how are males and females different over all of it, but to say, OK, well let's ask a specific question.
- 34:24And so I think some people are really excited about that.
- 34:26And then some people in my lab are more excited about these other questions that maybe are even simpler.
- 34:30Does zooming go up or down to this stimulus or that stimulus?
- 34:33Are drugs different after this experience?
- 34:36And so I have a good mix of both, but I think they really push each other.
- 34:39The the, the people studying sex references are looking at the people studying basic mechanisms saying, "Who cares?
- 34:45Explain to me why this is important." And then the people studying basic mechanisms are saying,"Whoa, that's really complex.
- 34:50How do you distill this down to something that's that's testable and clear?" And I think it kind of makes the science better on both sides.
- 35:12Really exciting for me to think about the, uh, all that work in terms of those models and how that, how does it translate to, again, not just how people understand the problem, but you know, when you're thinking about the questions that, that people were asking, like, um, what's the interference or, uh, promotive effect of a birth control pill, for example.
- 35:30Yes.
- 35:31Um, does this enter into whether treatment should look different for women who are facing, um, trying to reduce, uh, addictive behavior, uh, versus men?
- 35:40Or do you feel, like, "Whoa, too many steps, I don't wanna go there." I think the big, so for me to go there would be too many steps.
- 35:46But I do think the big thing that a lot of our studies have shown is that in the human literature, we we're not collecting that data, like, to the extent that we should have been.
- 35:56And so I think in the last few years, people have started doing that—to ask about menstrual cycle, have hormone data, and, and start to say, like, well, can we see in humans, are these things really influencing behavior?
- 36:08Like, they're influencing learning on these kind of small timescales and controlled experiments.
- 36:12But, like, how much of that variance is really the thing driving behavior, or is it just like a minuscule thing that kind of adds together with all of our experiences to kind of push things in one way or another?
- 36:23And so for me, you know, the human space is, like, so far out of my, like, experimental realm.
- 36:29But it's kind of allowed us to have these conversations with people who are doing epidemiology work or people actually working with clinical patients to say, "These are the things we see and these are the things that we don't." Yeah.
- 36:41And so I, you know, it helps me go back and redesign our experiments and so people are really interested in this.
- 36:46But also, you know, we're talking about how hormones affect drugs, but drug use affects your hormonal cycles as well.
- 36:51And so that's a big thing is, like, repeated drug use and how that changes hormones and how that could influence behavior, the brain stress, anxiety, and so there is, I think a, a link there that needs to be considered.
- 37:02And I think people are starting to consider it. There's there's some...
- 37:05And you pointed out in a recent ...
- 37:06I was just listening to a different podcast that you recorded with, um, two grad students— um, you were, I think at a conference— and, um, you talked about the way in which many, many drug trials funded by NIH didn't require, uh, if they were rodent models, for example, didn't require the inclusion of both sexes, right?
- 37:25And so from my perspective, I totally can see where, you know, for many, many scientists, this means having to go back and think differently, right?
- 37:34Test differently.
- 37:35Yeah.
- 37:36Yeah.
- 37:36And so, OK, so we ... This was a big issue.
- 37:38So the NIH basically mandated, probably, I mean, it was when I was in my postdocs, so it was some time ago now.
- 37:44Where they said, "Hey, we need you to have both males and females." And they said, you know, "You don't have to study sex differences for every study, but you can't just do all of your studies only in males." And that's what we were doing for, for a hundred years.
- 37:56Basically only 5 percent of all studies in the preclinical space were even powered to be able to detect ...
- 38:02Wait, did you just say five percent?
- 38:03Five percent of all the studies in that space were even adequately powered to be able to tell if you even had sex differences.
- 38:11And so you're going back and saying, "OK, well some of these textbook mechanisms for how the brain works were defined in males. But we know there's developmental and organizational and activational effects of hormones.
- 38:22And some of our work that we're working on now, which will come out at some point soon—we've submitted it—is really looking at how some of these mechanisms for dopamine regulation are just not present in intact females under certain conditions because hormones change the way receptors work.
- 38:36And so, you know, you start to look at, like, our foundation of science and how we're using that to develop drugs and treat people and you're saying, "Wait, this was all developed only in males?" And so it's...
- 38:48sex differences aren't, like,"Everybody's different in every way," right?
- 38:51But there are some nuances that affect women's health, like toxicity, metabolism, that there was ...
- 38:58I mean, just dose, right?
- 38:59Just dose.
- 38:59Just thinking about the amount that, you know.
- 39:02There's, I have some studies, I should look at the years again, but there was like a three-year period where 10 drugs were withdrawn by the FDA, and eight out of those 10 were withdrawn for having adverse health effects in women.
- 39:11Mm-hmm.
- 39:11And so these kinds of things that you think of as maybe not, oh, well, we're just studying dopamine and we're just studying this.
- 39:17These things really do compound down the pipeline to change how effective— are we targeting the right things?
- 39:24Are women experiencing the world differently?
- 39:25Do they have different stressors?
- 39:26Are those things influencing addiction differently?
- 39:29And so I think even these basic studies where you're just saying,"Where are the differences?
- 39:34How are they?
- 39:35How much are hormones involved?
- 39:36Where are they changing the brain?" They seem really basic, but they have a really large impact on starting to conceptualize and think about how to include women's health in the studies that we're doing.
- 39:46So, so powerful, right?
- 39:48Because you're saying, I mean, as I hear you.
- 39:50I don't require you to study sex differences, but I do require that if you're going to study something with federally funded tax dollars right, or federally funded, uh, support, um, that you actually are powered enough statistically...
- 40:04Yeah.
- 40:04...to detect if there's a iatrogenic or negative effect, or if there's a, a, a salutary or positive effect that we didn't anticipate, right?
- 40:11Or or justify where you, where you wouldn't, I mean, there's like, yes, if you're looking at maternal behavior, you don't need to include males in those studies. Right?
- 40:17If you're looking at specific effects that are affecting specific factors that influence men, like, OK, that's fine.
- 40:24But most neuroscience studies and most studies in my space, there...
- 40:28there is no "The Brain." Yeah, the brain.
- 40:30Like what?
- 40:30Like we're developing all of this understanding of the brain, but only in one sex?
- 40:35It's, like, it's a pretty large problem for starting to rewrite, like, all of these textbook mechanisms— how many of those are exactly the same in in in females?
- 40:44And some of them the answer is yes, and probably many of them the answer is yes. But you still need to know that.
- 40:48Totally.
- 40:49And so do your undergrads get that that's a new way to look at the ... at the world?
- 40:55Or at an important, uh, major intervention on the field?
- 40:59Or are they, you know, coming into the lab, like, "Of course, of course we should be including." You know, I mean, I, I'm curious just about how much, um, your 18- to 21-year-old...
- 41:10Yeah.
- 41:11...newest members of science are, like, setting a different standard or coming in with a different set of expectations.
- 41:17The, the, the best thing about this job is that, like, I get older, but everyone I work with stays the same age.
- 41:22And you get to see how the next generation is changing and how educated they are, how much information they have.
- 41:28I think for them it's, like,"Yeah, of course you should have both of these things." But what I try to do when I teach classes is explain to them, like, OK, let's say you don't care, this isn't something that, like, you're passionate about.
- 41:38Let's talk about how studying sex differences can actually be used as a mechanism to understand fundamental aspects of biology.
- 41:44Like, let's say you're studying how a receptor regulates dopamine release, but in females it doesn't.
- 41:51Well, now you have a biologically relevant scenario—where that receptor does X and Y—that you can start to do studies to manipulate, well, in which cases where it's not there—what does behavior look like?
- 42:01So I, I try to, Right, you have a a a basically built-in knockout gene, right?
- 42:05Yeah.
- 42:05So, so I think I, I, I look, and I say,"Look, OK, this is something we need to do from like a societal standpoint.
- 42:10But also, like, think about this as an opportunity to understand how variation in neural systems and behavior influences our experience in the world." And so I think my goal is to try to get people to understand how important this is.
- 42:24And I think you have to meet them where they ... where they are.
- 42:26Like, you meet some people and they say, "Yes, I get it." And you say, "Great, let me give you the tools." And other people are, like, "Eh, I don't care." And I'm, like, "Let me show you some other ways that this could be used— even if that's not your key question." And so it's kind of exciting.
- 42:38It's a challenge for me, but it also kinda keeps me on my toes.
- 42:41Absolutely.
- 42:42And, uh, generally, are students understanding themselves to be future scientists?
- 42:47Who's in your class?
- 42:48What...
- 42:48Yeah.
- 42:49...are those students thinking they're, they are in the class to learn?
- 42:52Yeah.
- 42:52So, OK.
- 42:53We have a good mix of people.
- 42:55I, I think like one of the coolest things is how ...
- 42:58how they're kind of going beyond these traditional paths.
- 43:01Like, you know, it's like you go here, then academia. These students are rewriting, kind of, what things look like for them.
- 43:07They're collaborating across colleges, they're doing immersion projects.
- 43:11I ... a lot of them, I think, come in not necessarily knowing what an academic career looks like.
- 43:16It's not something, if you haven't experienced it with your family, that you really get until you get to an undergrad institution where you say, "Oh, I can just, like, learn stuff all the time?" Totally.
- 43:25"As my job?" And so you have some of that.
- 43:28You have, you have people that wanna go into the medical profession, which I see this as an opportunity for me to explain to them, kind of, why these things are important.
- 43:34You have people who really wanna do drug discovery. Again, like, this kind of work is really critical.
- 43:39And then you have people who wanna come up with solutions that I can't even think of for problems that we haven't encountered yet that develop, you know, their own companies.
- 43:48And so you have this really diverse perspective.
- 43:50And, and as a, as an educator, you're sitting there saying, "How do I engage all of these different people?" And I do think that that makes my science better because it's that"Who cares?
- 44:01Why would all of, why would all of these people care?" that really makes me think about my work in that context.
- 44:05How do I convince these people it's important?
- 44:07And if I can't, maybe it isn't.
- 44:09And so, which, which is sometimes sad, but, like...
- 44:12No, but what a scientific approach to your own...
- 44:14Yeah.
- 44:14Yeah.
- 44:14So, so I, I, I try to educate them, but then I kind of look at what, what they are seeing as the next, the next thing and what they are looking to get out of this.
- 44:22And I say, one, I'm gonna try to convince you to come over to my academic side, but I also want you to, kind of, help me shape what we think is, is important.
- 44:29It's, it's, it's fun.
- 44:30It's just great.
- 44:31I'm, they're so lucky to have you, Erin.
- 44:33It's just wonderful.
- 44:35I think when I, um, have a chance to step back, I, I immediately wanna know, um, what you really want us to have as a key takeaway.
- 44:43You know, if you're thinking about, um, someone who isn't, uh, at Vanderbilt or isn't part of a university community, and they've heard you talk about this incredible role of, you know, the endocrine system, uh, and dopamine and, uh, drug use.
- 44:59From all of the things that you've just, um, shared with us—what's a key thing that you want us to take away?
- 45:05Yeah.
- 45:05That things are way more complicated than we think.
- 45:07They, they, I think that we, as humans, like very simple explanations for things.
- 45:12And I think in some level that's amazing, right?
- 45:15But I think that things are really complex, and I think thinking deeper— and you can't think deeply about everything—but about things that are important to you, I think, really opens up how you approach the world.
- 45:26And so I think the dopamine work we do is a really good example of ... is a reward molecule.
- 45:30Well, why do we think that?
- 45:32And you start to see that that's more complicated.
- 45:34And thinking about how hormones influence that and how you can change how you learn at specific times is also interesting.
- 45:40And so I think, like, what is the take home?
- 45:42The take home is that, that the brain is a really complex organ that helps us learn and adapt to our environment in a way that is efficient and interesting.
- 45:53And that there's lots of things in our environment that can hijack that for better or worse?
- 45:58Yeah.
- 45:58I mean, profoundly hopeful to me.
- 46:00Yeah.
- 46:00Right.
- 46:00Mm-hmm.
- 46:00Because in a, in a key way, it's not just a person, uh, with a set of test tubes and a set of mice, um, trying to figure out, um, a special arcane pathway.
- 46:11You're actually trying to address, um, the potential for, um, you know, human flourishing in the face of something that I think for many of us seems really scary— the opioid epidemic seems, you know, intractable, Yeah.
- 46:25right?
- 46:25Yeah.
- 46:25But you're demonstrating all these amazing, hopeful avenues that we've only just begun to pursue.
- 46:31Yeah.
- 46:32And I think that's the interesting thing.
- 46:33And the fact that people are becoming more and more interested in getting accurate, factual information— I think it's just such a cool ... it's a cool time that we are able to kind of put this out there and people actually want to engage and understand it deeper.
- 46:46And I think that bodes really well for human disease as well, because it means people are going to be invested in solving this problem in a way that we maybe weren't in the past.
- 46:55Thank you so much, Erin.
- 46:57And, uh, thanks to our listeners for tuning in.
- 47:00We'll be back next time with another guest who's pushing the boundaries of discovery.
- 47:04Until then, I really wanna thank Erin Calipari, uh, for her leadership and her amazing, groundbreaking science.
- 47:11And, uh, I really wanna thank every one of you for having tuned in.
- 47:14I'm Cybele Raver, and this is 'Quantum Potential.' The 'Quantum Potential' podcast comes from Vanderbilt University.
- 47:31Your host is C. Cybele Raver. Thank you to our guest, Eric Calipari.
- 47:37Production by Matriarch Digital Media.
- 47:40For more information about'Quantum Potential,' go to vanderbilt.edu/quantum potential.
- 47:49Stay curious.